Med-Fine Capital

Allink Biotherapeutics is a biopharmaceutical company that focuses on oncology and immunological treatment.

BV Laser is a manufacturer of medical beauty equipment.

ZD Medical develops innovative medical imaging technology, specifically phase variance optical coherence tomography, which enables the simultaneous detection of macular degeneration and retinal microvascular proliferation caused by diabetes. This non-invasive technology is designed for early detection of diabetic retinopathy, assisting healthcare professionals in identifying internal symptoms in patients. The company brings together a team of scientific and technological experts from various backgrounds to advance the development and manufacture of high-quality medical devices. ZD Medical is committed to providing practical solutions for medical diagnosis and clinical treatment, ultimately aiming to enhance healthcare outcomes and benefit public health.

PuJu Biotech focuses on developing an engineering process platform for bioactive filling materials and is dedicated to continuously launching world-class high-end regenerative medicine material products to benefit the vast number of people seeking beauty, as well as providing new material solutions for medical beauty and anti-aging for all age groups.

Zhuanma Biotechnology is a gene editing service provider dedicated to clinically developing effective ultra-small gene editors into genetic therapeutics that are "curable once and for all."

Rebecca is committed to the application of precision-controlled MEMS radio frequency technology in clinical disease control and rehabilitation. Its core technology comes from the core team's many years of experience and achievements in research and development and productization at the University of California, Fortune 500 medical equipment, and electronic equipment companies. The company cooperated with domestic university research institutes and many top three hospitals in Beijing, Shanghai, and Hangzhou to independently develop micro-radio frequency technology that surpassed similar products in Europe and America. It focuses on delivering innovative medical solutions to the hands of professional caregivers. Rebecca's team possesses technical expertise in micro-devices, RF, and device integration through years of field practice in micro-electronics and clinical innovation.

Danatlas is a pharmaceutical company that develops drugs designed for oncology treatment. It also provides drug research and development in the fields of cancer, inflammation, blood, and metabolic diseases.

Med-Vision is a developer of virtual reality-based therapy focused on enhancing medical care services. The company provides hospitals and rehabilitation centers with innovative solutions for mental and psychological health conditions, physical rehabilitation, and cognitive therapies, particularly for the elderly. By integrating digital gaming features into post-treatment health management, Med-Vision creates immersive simulations that support psychotherapy and psychological rehabilitation. This approach enables healthcare providers to develop precise treatment plans, ultimately improving patient outcomes and experiences in various therapeutic settings.

VelaVigo is a start-up company engaged in macromolecular biopharmaceuticals.

Leadinno Medical Valley specializes in the production of medical devices aimed at neuroregulatory functions. The company develops implantable neuroelectric stimulation products designed to treat various neurological functional diseases. By leveraging innovative technologies, Leadinno focuses on creating wireless energy-carrying implantable devices that enhance patient comfort and aim to lower treatment costs.

Degron Therapeutics is a drug discovery platform focused on developing a new class of targeted protein degradation therapeutics, specifically small molecule molecular glue degrader drugs. The company aims to become a leader in the discovery and development of these innovative medicines, which target disease mechanisms that are often inaccessible to traditional small molecule inhibitors. By leveraging its advanced molecular glue protein degradation platform technology, Degron Therapeutics identifies and validates disease targets while creating novel selective compounds. This approach addresses significant unmet medical needs across various therapeutic areas. The company boasts a team of experienced executives and scientific leaders dedicated to enhancing treatment efficiency through its drug development initiatives.

Weimi Bio-Tech specializes in the development of innovative in vitro diagnostic products, focusing on immunofluorescence chromatography technologies. Their offerings are utilized in a variety of medical applications, including inflammation detection, prenatal testing, cervical cancer diagnosis, and cardio-cerebral-vascular assessments. The company aims to deliver reliable and effective diagnostic solutions for medical practitioners, supporting the needs of medical laboratories with comprehensive product solutions and services.

Med-Vision is a developer of virtual reality-based therapy focused on enhancing medical care services. The company provides hospitals and rehabilitation centers with innovative solutions for mental and psychological health conditions, physical rehabilitation, and cognitive therapies, particularly for the elderly. By integrating digital gaming features into post-treatment health management, Med-Vision creates immersive simulations that support psychotherapy and psychological rehabilitation. This approach enables healthcare providers to develop precise treatment plans, ultimately improving patient outcomes and experiences in various therapeutic settings.

CorrGene is an innovative company focusing on the research and development and production of new anti-cancer drugs and rare diseases with gene editing technology and cell therapy. The company was established by a group of cell and gene therapy experts, virologists, oncologists, hematologists and biopharmaceutical industry veterans. CorrGene was established in January, 2022 in Jiangsu, China.

Westlake Omics is a biotechnology company based in Hangzhou, Zhejiang, China, founded in 2020. It specializes in mass spectrometry-based proteomics and other Omics technologies to meet critical clinical needs. The company aims to advance precision medicine and drug research and development by utilizing artificial intelligence for high-throughput proteomic analysis of small clinical specimens. Through its innovative approach, Westlake Omics focuses on enhancing the accuracy of tumor diagnosis and developing reliable, cutting-edge products that address significant health challenges. By integrating technological advancements and multi-modal big data, the company is dedicated to making meaningful contributions to the field of clinical diagnostics.

AccuPulse is focused on the development of a pulsed electric field ablation (PFA) system designed to treat atrial fibrillation (A-fib). The company offers a comprehensive solution that includes both a PFA generator and specialized catheters for the pulse ablation of A-fib and tumors. By integrating advanced technologies, AccuPulse aims to enhance catheter localization and signal acquisition, while also improving the overall efficiency of interventional therapies that utilize radio frequency and cryotherapy. This innovative approach seeks to provide healthcare professionals and patients with a more effective and intelligent treatment option for managing A-fib and related conditions.

Allorion Therapeutics is a small molecule therapeutic development company dedicated to creating innovative treatments for cancer and autoimmune diseases. With operational facilities in Natick, Massachusetts, and Guangzhou, China, Allorion specializes in developing mutant selective and isoform-specific drugs through unconventional methods targeting established disease pathways. This approach aims to enhance the efficacy of treatments and reduce the likelihood of resistance in patients, contributing to improved therapeutic outcomes.

PharmaLegacy Laboratories provides pharmacology services in inflammation and auto-immune diseases. Their services include pharmacokinetics, pharmacodynamics, toxicology, non-human primate studies, histopathology, biomarker detection, medical device testing, and DMPK. They also provide oncology, immuno-oncology, inflammation, immunity, autoimmunity, metabolic disease models, hepatic, renal disease models, cardiovascular disease models, pulmonology, lung disease models, bone, orthopedics, ophthalmic disease models, otology, and pain models.

Epintek specializes in the biomedical and medical device sectors, offering a range of services that include preclinical research, inspection, and testing. The company serves as a contract research organization (CRO) for medical institutions and manufacturers of medical equipment. By providing reliable preclinical inspection services, Epintek supports clients in navigating the complexities of regulatory requirements, including registration and clinical trials.

Med-Vision is a developer of virtual reality-based therapy focused on enhancing medical care services. The company provides hospitals and rehabilitation centers with innovative solutions for mental and psychological health conditions, physical rehabilitation, and cognitive therapies, particularly for the elderly. By integrating digital gaming features into post-treatment health management, Med-Vision creates immersive simulations that support psychotherapy and psychological rehabilitation. This approach enables healthcare providers to develop precise treatment plans, ultimately improving patient outcomes and experiences in various therapeutic settings.

Immunophage Biotech is a Chinese high-tech pharmaceutic company which was established in 2016. The R&D center of the company is located in the Pujiang High-Tech Park, Shanghai, China. They are developing first-in-class immune-regulating medicines against cancer, autoimmune diseases and neurodegenerative disorders.

LYNK Pharmaceuticals is a biotechnology company based in Hangzhou, China, specializing in the development of small molecule drugs aimed at treating tumors and autoimmune diseases. Founded in 2017, the company focuses on the discovery and development of innovative medicines in the fields of oncology, immunology, and inflammatory diseases. Its business operations include new drug research, sales, and activities related to patent authorization and transfer.

Zhongguancun Shuimu Medical Technology is the operator of a third-party, competent medical device compliance organization. Their business helps companies cut costs and time to market by offering medical device compliance services. It is dedicated to accelerating the registration and listing procedures for new medical device items as well as addressing the issue of how to industrialize creative medical device firms.

Zion Pharma is a drug discovery platform focused on developing innovative small molecule drugs for oncology, particularly targeting unmet medical needs in cancer treatment. The company specializes in creating "me-better" drugs that aim to improve upon existing therapies, with a commitment to delivering differentiated "best-in-class" and "first-in-class" treatments. Zion's research and development efforts are concentrated on addressing specific challenges in oncology, including breast cancer brain metastasis, thereby enabling healthcare professionals to better meet clinical demands.

Leadinno Medical Valley specializes in the production of medical devices aimed at neuroregulatory functions. The company develops implantable neuroelectric stimulation products designed to treat various neurological functional diseases. By leveraging innovative technologies, Leadinno focuses on creating wireless energy-carrying implantable devices that enhance patient comfort and aim to lower treatment costs.

Weiyan Medical Technology (Beijing) Co., Ltd. specializes in clinical infectious pathogen detection services, utilizing advanced technology for precise molecular diagnostics. Founded in 2019 and based in Beijing, the company operates an artificial intelligence platform tailored for medical bioinformatics. It employs a range of sequencing technologies, including NovSeq6000 for human genome sequencing, Nextseq550 Dx for diverse applications, Nanopore for pathogen detection, MGISEQ-2000 for optical and biochemical analysis, and Ion GeneStudio S5 for semiconductor sequencing. Additionally, Weiyan Medical provides chemical reagents through its Ion Hi-Q system, enhancing its capabilities in the diagnostics sector.

Alebund Pharmaceuticals is a biopharmaceutical company focused on developing innovative therapies for renal diseases and related chronic conditions. The company specializes in the research, development, regulatory approval, and commercialization of medicines aimed at treating various kidney diseases, including chronic kidney disease, complications associated with dialysis, nephropathy, diabetic kidney disease, and autosomal dominant polycystic kidney disease. With a diversified and balanced pipeline of drug candidates, Alebund Pharmaceuticals aims to provide comprehensive and high-quality solutions for patients suffering from renal diseases.

Artivila Therapeutics is a pharmaceutical company established in 2018 and based in Shenzhen, China. The company specializes in biotechnology and is dedicated to improving patient outcomes through innovative drug discovery. Utilizing an AI-powered platform, Artivila focuses on developing new therapeutic solutions for neurodegenerative diseases, cancers, and autoimmune diseases. Its integrated approach aims to consistently and efficiently deliver first-in-class drug candidates, positioning Artivila at the forefront of pharmaceutical research and development.

Juncell Therapeutics focuses on developing innovative therapies and pharmaceutical drugs specifically for tumor treatment. The company specializes in tumor cell therapy, offering solutions to isolate tumor-infiltrating lymphocytes (TILs) from tumor tissues. These TILs are subsequently developed outside the human body and re-injected into patients, allowing for targeted treatment of tumors. This approach aims to enhance the effectiveness of cancer therapies while minimizing side effects, ultimately improving patient outcomes in the fight against cancer.

Ultrast is a medical company engaged in the production, and sale of medical platforms and surgical robots.

Commbio Therapeutics focuses on developing genetically engineered bacteria for treating complex diseases in the field of intestine biology.

Allorion Therapeutics is a small molecule therapeutic development company dedicated to creating innovative treatments for cancer and autoimmune diseases. With operational facilities in Natick, Massachusetts, and Guangzhou, China, Allorion specializes in developing mutant selective and isoform-specific drugs through unconventional methods targeting established disease pathways. This approach aims to enhance the efficacy of treatments and reduce the likelihood of resistance in patients, contributing to improved therapeutic outcomes.

Alebund Pharmaceuticals is a biopharmaceutical company focused on developing innovative therapies for renal diseases and related chronic conditions. The company specializes in the research, development, regulatory approval, and commercialization of medicines aimed at treating various kidney diseases, including chronic kidney disease, complications associated with dialysis, nephropathy, diabetic kidney disease, and autosomal dominant polycystic kidney disease. With a diversified and balanced pipeline of drug candidates, Alebund Pharmaceuticals aims to provide comprehensive and high-quality solutions for patients suffering from renal diseases.

PharmaLegacy Laboratories provides pharmacology services in inflammation and auto-immune diseases. Their services include pharmacokinetics, pharmacodynamics, toxicology, non-human primate studies, histopathology, biomarker detection, medical device testing, and DMPK. They also provide oncology, immuno-oncology, inflammation, immunity, autoimmunity, metabolic disease models, hepatic, renal disease models, cardiovascular disease models, pulmonology, lung disease models, bone, orthopedics, ophthalmic disease models, otology, and pain models.

BioNova Pharma biopharmaceutical company that develops and commercializes innovative medicines for cancer and other life-threatening diseases. The company is expanding company with a strong pipeline based on in-house R&D initiatives, partnerships with, and purchases from partners with cutting-edge technology. The goal of BioNova is to close the gap between the high unmet medical needs and the dearth of innovative medicines by developing an innovative R&D platform with a substantial pipeline to address multiple disease areas.

ClinBrain develops a hospital information integration platform aimed at improving healthcare services through the digitization and standardization of patient data alongside medical and clinical data. This platform is designed to enhance the efficiency of medical research by providing hospitals with comprehensive healthcare big data services. By facilitating the integration of diverse data sources, ClinBrain supports healthcare professionals in making informed decisions and advancing medical research initiatives.

Shenzhen VitaVitro Biotech Co., Ltd. is a biotechnology company specializing in assisted reproduction technology. Established in 2015 and headquartered in Shenzhen, China, the company offers a comprehensive range of products and services for assisted reproduction laboratories worldwide. Its offerings include cryopreservation solutions, various culture and flushing media, gamete buffer mediums, and labware, all designed to enhance the efficiency and success rates of in vitro fertilization (IVF) procedures. VitaVitro's focus is on addressing infertility challenges by providing integrated solutions that encompass the entire IVF process, from egg retrieval and freezing to embryo culture and transfer, ultimately aiming to optimize embryo quality and increase pregnancy rates for its clients. The company has expanded its presence with offices in Europe, America, and the Asia Pacific region.

Hanyu Medical is a pioneering company in the development, production, and sale of transcatheter mitral valve repair devices, focusing on innovative solutions for heart valve diseases. Its primary product, Valve Clamp, is an interventional device designed for minimally invasive treatment of mitral valve regurgitation. This device facilitates the closure of heart valves during operations, allowing surgeons to perform heart surgeries with reduced invasiveness. Hanyu Medical's commitment to advancing medical technology positions it as a significant player in the cardiovascular device market.

Zion Pharma is a drug discovery platform focused on developing innovative small molecule drugs for oncology, particularly targeting unmet medical needs in cancer treatment. The company specializes in creating "me-better" drugs that aim to improve upon existing therapies, with a commitment to delivering differentiated "best-in-class" and "first-in-class" treatments. Zion's research and development efforts are concentrated on addressing specific challenges in oncology, including breast cancer brain metastasis, thereby enabling healthcare professionals to better meet clinical demands.

Zhongyianke Biotech specializes in the development and provision of human vaccines. The company has successfully launched a flu vaccine and is advancing its research with multiple products currently in clinical trials, including a tetravalent influenza vaccine, a tetravalent meningococcal vaccine, a rabies vaccine, and a rubella vaccine. Zhongyianke holds 14 patents in China, underscoring its commitment to innovation in vaccine technology. With operations centered in Tianjin, the company also maintains a research and development center in Beijing and a production facility in Liaoning Province, enhancing its capacity to contribute to public health through its vaccine offerings.

ChosenMed is a healthcare company specializing in oncology precision medicine. It is dedicated to early tumor screening and companion diagnosis, aiming to improve patient outcomes in cancer care. The company develops products that address the early screening, prevention, and diagnosis of tumors. Additionally, ChosenMed provides guidance for targeted medication related to solid tumors and predicts the efficacy of tumor immunotherapy. By offering a comprehensive range of precision medical solutions and immunotherapy options, ChosenMed strives to enhance treatment effectiveness and support personalized patient care in oncology.

LYNK Pharmaceuticals is a biotechnology company based in Hangzhou, China, specializing in the development of small molecule drugs aimed at treating tumors and autoimmune diseases. Founded in 2017, the company focuses on the discovery and development of innovative medicines in the fields of oncology, immunology, and inflammatory diseases. Its business operations include new drug research, sales, and activities related to patent authorization and transfer.

Ranok Therapeutics is a biotechnology company focused on developing targeted protein degradation technology to discover and create new therapeutics. This innovative approach engages various biological processes and demonstrates superiority over existing targeted protein degradation methods. The company's pipeline includes both well-established and novel drug targets associated with cancer and other diseases that present significant unmet medical needs. Ranok is committed to advancing the next generation of cancer therapies that prioritize safety and effectiveness for patients facing serious health challenges.

Tyligand Bioscience (Shanghai) Limited is a biotechnology company founded in 2013 and based in Shanghai, China. The company specializes in the development and manufacturing of small molecule therapeutics aimed at treating cancer and autoimmune diseases. Tyligand's pharmaceuticals are specifically designed to target tumors and autoimmune disorders, thereby enhancing the efficacy of treatment options available to healthcare professionals and improving patient health outcomes.

Alebund Pharmaceuticals is a biopharmaceutical company focused on developing innovative therapies for renal diseases and related chronic conditions. The company specializes in the research, development, regulatory approval, and commercialization of medicines aimed at treating various kidney diseases, including chronic kidney disease, complications associated with dialysis, nephropathy, diabetic kidney disease, and autosomal dominant polycystic kidney disease. With a diversified and balanced pipeline of drug candidates, Alebund Pharmaceuticals aims to provide comprehensive and high-quality solutions for patients suffering from renal diseases.

AMCARELAB is an independent medical service organization providing diagnosis and consultant for hereditary & oncological diseases.

Suzhou Xinqing Medical Technology Co., Ltd., founded in 2017 by Dr. Xu Bozhen, focuses on the development of in-vitro artificial heart devices aimed at assisting patients with cardiovascular illnesses. The company specializes in creating short-term to medium-term ventricular assist devices that leverage advanced fluid mechanics and magnetic suspension technology. These innovations allow the devices to be compatible with various blood types, thereby reducing the risk of incompatibility for patients. With a team of leading experts in artificial heart engineering, the company has successfully developed an artificial heart that holds independent intellectual property rights, positioning itself as a key player in the medical technology sector.

Leto Laboratories focuses on research and development in the field of protein re-engineering, aiming to address gaps in the treatment of cancer and rare diseases. The company employs advanced technologies, including high-throughput protein re-screening, purification, and drug formulation development platforms. By leveraging these innovative approaches, Leto Laboratories strives to create more effective protein-based therapies, enhancing treatment options for patients. The diverse research team works collaboratively to advance the company's mission of improving healthcare outcomes through specialized protein technology.

ZD MedTech, also known as Zhuo Dao Medical, specializes in the development of rehabilitation robots and intelligent rehabilitation solutions tailored to the clinical needs of Chinese medicine and its patients. The company boasts a domestic research and development team focused on creating advanced robotic assistive technology that enhances rehabilitation processes. Its offerings include high-end rehabilitation robots and exoskeleton training devices designed to facilitate upper limb recovery. By integrating rich training modes and effective human-computer interaction within its intelligent rehabilitation management system, ZD MedTech aims to improve patient outcomes and expedite rehabilitation treatments. Through ongoing innovation and adaptation to the evolving landscape of rehabilitation medicine, the company is committed to advancing the field and supporting the recovery journey of patients.

Zion Pharma is a drug discovery platform focused on developing innovative small molecule drugs for oncology, particularly targeting unmet medical needs in cancer treatment. The company specializes in creating "me-better" drugs that aim to improve upon existing therapies, with a commitment to delivering differentiated "best-in-class" and "first-in-class" treatments. Zion's research and development efforts are concentrated on addressing specific challenges in oncology, including breast cancer brain metastasis, thereby enabling healthcare professionals to better meet clinical demands.

Oceanus Plus is a China-based company dedicated to the development of clinical trial management systems and clinical research products. The company holds independent intellectual property rights, allowing it to create innovative solutions tailored for the clinical research industry. By focusing on these areas, Oceanus Plus aims to enhance the efficiency and effectiveness of clinical trials, contributing to advancements in medical research and healthcare outcomes.

Immvira, founded in Shenzhen, China, in May 2015 by a group of prominent professors from various universities, is focused on developing biopharmaceutical technology in the field of immunotherapy. The company specializes in creating oncolytic viruses and vector-type approaches aimed at treating cancer. Its primary product is a genetically engineered Oncolytic Herpes Simplex Virus, which is designed to target metastatic tumors or tumors that are difficult to access by direct injection. By leveraging this innovative technology, Immvira aims to provide more effective treatment solutions for patients suffering from cancer.

Cherubs is a baby formula milk powder manufacturer.

Beijing Saifu Medical Research Institute Co., Ltd. relies on the Shanghai Institute of Materia Medica of the Chinese Academy of Sciences and the National Drug Safety Evaluation and Research Center of the State of Beijing to establish strategic partnerships with them to form a combination of technology, capital and enterprise operations. The core members of the company are researchers of the Institute of Materia Medica of the Chinese Academy of Sciences and researchers of the Academy of Military Medical Sciences. They have high scientific research and academic status in the fields of drug research and development and toxicology research, as well as rich drug development, GLP management and technical experience, and build and operate the platform. Provides strong talent and technical support.

Weimi Bio-Tech specializes in the development of innovative in vitro diagnostic products, focusing on immunofluorescence chromatography technologies. Their offerings are utilized in a variety of medical applications, including inflammation detection, prenatal testing, cervical cancer diagnosis, and cardio-cerebral-vascular assessments. The company aims to deliver reliable and effective diagnostic solutions for medical practitioners, supporting the needs of medical laboratories with comprehensive product solutions and services.

Eccogene is a clinical stage biopharmaceutical company focused on developing therapeutic solutions for unmet medical needs, particularly in the areas of metabolism and immune-related diseases. The company specializes in disease biology, medicinal chemistry, and translational science, aiming to create immunological pharmaceuticals at the molecular level to address complex chronic conditions such as obesity and diabetes. Through its innovative approach, Eccogene is building a pipeline of metabolic drugs designed to enhance patient outcomes and improve health conditions related to these chronic diseases.

Shunzhi Technology is a Healthcare company.

Gaugene specializes in providing advanced hematology testing instruments, reagents, and services tailored for in vitro diagnostic (IVD) users. As a high-tech enterprise, it is backed by experienced professionals from prominent domestic IVD companies who possess expertise in leading-edge technologies. The company’s instruments are unique in China, featuring high-power flow lasers and high-sensitivity multi-color fluorescence detection systems. These innovations enable a wide range of applications, including hematology diagnosis, clinical diagnosis, and life science research. Gaugene's solutions support clinical diagnostics and flow cytometry technology, facilitating single-cell research, protein screening, and the discovery of new clinical indicators.

ChosenMed is a healthcare company specializing in oncology precision medicine. It is dedicated to early tumor screening and companion diagnosis, aiming to improve patient outcomes in cancer care. The company develops products that address the early screening, prevention, and diagnosis of tumors. Additionally, ChosenMed provides guidance for targeted medication related to solid tumors and predicts the efficacy of tumor immunotherapy. By offering a comprehensive range of precision medical solutions and immunotherapy options, ChosenMed strives to enhance treatment effectiveness and support personalized patient care in oncology.

Zion Pharma is a drug discovery platform focused on developing innovative small molecule drugs for oncology, particularly targeting unmet medical needs in cancer treatment. The company specializes in creating "me-better" drugs that aim to improve upon existing therapies, with a commitment to delivering differentiated "best-in-class" and "first-in-class" treatments. Zion's research and development efforts are concentrated on addressing specific challenges in oncology, including breast cancer brain metastasis, thereby enabling healthcare professionals to better meet clinical demands.

Julu Medical specializes in digital rehabilitation technology, focusing on the development of clinical therapies for patients with cardiac and pulmonary conditions. The company provides a range of services, including the construction of intensive care rehabilitation systems, cardiac rehabilitation systems, respiratory rehabilitation systems, and facilities dedicated to the rehabilitation of elderly patients with cardiopulmonary chronic diseases. Julu Medical aims to enhance the quality of life for individuals suffering from cardiac diseases through innovative rehabilitation solutions.

LYNK Pharmaceuticals is a biotechnology company based in Hangzhou, China, specializing in the development of small molecule drugs aimed at treating tumors and autoimmune diseases. Founded in 2017, the company focuses on the discovery and development of innovative medicines in the fields of oncology, immunology, and inflammatory diseases. Its business operations include new drug research, sales, and activities related to patent authorization and transfer.

Hanyu Medical is a pioneering company in the development, production, and sale of transcatheter mitral valve repair devices, focusing on innovative solutions for heart valve diseases. Its primary product, Valve Clamp, is an interventional device designed for minimally invasive treatment of mitral valve regurgitation. This device facilitates the closure of heart valves during operations, allowing surgeons to perform heart surgeries with reduced invasiveness. Hanyu Medical's commitment to advancing medical technology positions it as a significant player in the cardiovascular device market.

Genomeprecision is a molecular diagnostic enterprise integrating R&D, production and sales. It has established “real-time fluorescent quantitative PCR”, “first-generation Sanger sequencing”, “second-generation high-throughput NGS sequencing” and “capillary electrophoresis”. "Fragment Analysis" and "Chemiluminescence CLIA" five molecular diagnostic technology platforms, we will be based on clinical diagnosis and treatment needs to develop molecular diagnostic products based on the above technology platform.

Beijing Mabworks Biotech, a gene engineering mAb company. Mabworks is working on ZMapp, an Ebola treatment developed by San Diego's MAPP Biopharma. It also is developing two clinical stage drug candidates: MIL60, a biosimilar to Genentech's Avastin, and MIL62, a proposed treatment for chronic lymphocytic leukemia.

Surgnova, founded in 2015 by Huang Wenxing in Beijing, China, specializes in the development of minimally invasive surgical equipment and supplemental robotics aimed at tumor treatment. The company operates an R&D center featuring over ten laboratories focused on various fields, including electronics, machinery, optics, acoustics, and robotics. Surgnova has established three key platforms: an endoscopy platform, an energy surgery platform, and a tumor ablation platform. Their products enhance surgical precision and efficiency, allowing surgeons to perform procedures that minimize patient recovery time and bodily harm. Through its innovative solutions, Surgnova aims to provide high-quality surgical options to healthcare providers globally.

Biosis Healing specializes in regenerative medicine materials and implantable medical devices for clinical surgery. The company offers a range of innovative products designed for minimally invasive procedures, including regenerative surgical bio-materials, soft tissue repair mesh, and intelligent surgical instruments. Notably, its self-developed non-crosslinked Extracellular Matrix bio-material supports the regeneration of tissue defects, addressing issues related to tissue repair and functional regeneration following surgical resection. Biosis Healing aims to advance clinical technology and treatment methodologies in partnership with clinical specialists, continually developing unique products to enhance surgical outcomes across various medical fields, including hernia repair, dentistry, and neurosurgery.

Beijing Mabworks Biotech, a gene engineering mAb company. Mabworks is working on ZMapp, an Ebola treatment developed by San Diego's MAPP Biopharma. It also is developing two clinical stage drug candidates: MIL60, a biosimilar to Genentech's Avastin, and MIL62, a proposed treatment for chronic lymphocytic leukemia.

Health SAGE provides health services for back and pelvic problems. Health SAGE also provides extra services such as massages, neck and waist assessments, and jiannao head care. Health SAGE was established in 2014 in Shanghai, China.